Markets›Everest Medicines

Everest Medicines

HKEX:1952equity

28.74+0.38 (+1.34%)HKSE · HKD

HKEX:1952

Data: Yahoo Finance · Prices may be delayed 15–20 min

Previous close

28.36

Open

28.36

Day's range

28.36 – 29.24

52-week range

22.70 – 75.15

Volume

1,018,573

Currency

HKD

News

All news →

No news found for Everest Medicines.

Press Releases

All releases →

ACN Newswire

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

8 Jul 2026

ACN Newswire

Everest Medicines Announces NMPA Acceptance of the BLA for LEROCHOL(R), Offering a Potential New Treatment Option for Hypercholesterolemia in China

26 Jun 2026

ACN Newswire

Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules, further enhancing patient access to the medication

24 Jun 2026

ACN Newswire

Everest Medicines Enters into Exclusive Licensing Agreement with Dimerix for DMX-200 in Greater China, South Korea and Southeast Asia

16 Jun 2026

ACN Newswire

Everest Medicines Secures Exclusive License for Sumecigrel in Asia-Pacific, Expanding Its Cardiovascular Product Portfolio

9 Jun 2026

ACN Newswire

Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China, Strengthen Presence in Ophthalmology

8 Jun 2026

ACN Newswire

Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin(R) in the Asia-Pacific Market

4 Jun 2026

ACN Newswire

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

4 Jun 2026

Symbol: HKEX:1952Yahoo Finance: 1952.HKType: equityAlso known as: everest medicines · 1952.hk · 01952.hk

Market data is indicative and delayed 15–20 min. Not investment advice.